Interleukin Genetics, Inc. - ILI- Profile

Interleukin Genetics, Inc.. The Group's principal activity is to develop and commercialize genetic diagnostic tests and medical research tools. The Group develops and licenses its medical research tools, including BioFusion(R) to pharmaceutical companies. The Group has agreements with Sheffield University, Delta Dental, Kenna Technologies, Kaiser Permanente for product research and development. The Group's first genetic susceptibility test, PST, detects a genetic susceptibility to severe gum diseases (periodontitis). The Group's primary products include periodontal Susceptibility Test, a DNA test, which assesses risk for periodontal disease. Risk assessment products pipeline includes INT-484 personalized cardiovascular for coronary artery disease, INT-551 Personalized Periodontal for bacterial test of mouth flora, and INT-811 personalized osteoporosis for bone disease. The Group operates only in the United States. On 01-Feb-2005, the Group acquired Molecular SkinCare. Develops & Commercializes genetic diagnostic tests & medical research tools